Match!
Allan H. Young
King's College London
PsychiatryPsychologyBipolar disorderClinical psychologyMedicine
704Publications
77H-index
35.3kCitations
What is this?
Publications 680
Newest
#1Rebecca Strawbridge ('KCL': King's College London)H-Index: 8
#2Dimosthenis Tsapekos ('KCL': King's College London)H-Index: 2
Last. Clare Reeder ('KCL': King's College London)H-Index: 22
view all 13 authors...
OBJECTIVES Cognitive remediation therapy (CRT) may benefit people with bipolar disorder type I and II for whom cognitive impairment is a major contributor to disability. Extensive research has demonstrated CRT to improve cognition and psychosocial functioning in people with different diagnoses, but randomised trials of evidenced therapy programmes are lacking for bipolar disorders. The Cognitive Remediation in Bipolar (CRiB) study aimed to determine whether an established CRT programme is feasib...
Source
#1Allan H. Young ('KCL': King's College London)H-Index: 77
#2Calum D. Moulton ('KCL': King's College London)H-Index: 8
Source
#2Enrico Bugiardini (UCL: University College London)H-Index: 5
Last. N. James (UCL: University College London)H-Index: 1
view all 15 authors...
Primary mitochondrial diseases (PMD) are heterogeneous disorders caused by mutations in nuclear DNA-encoded and mitochondrial DNA (mtDNA)-encoded genes. Neurological impairment is common and reflects the susceptibility of the central nervous system to alterations in mitochondrial oxidative metabolism. Case reports and small-scale cross-sectional studies in PMD have suggested a high comorbidity with neuropsychiatric syndromes, including mood disorders (online supplementary table 1).1 However, the...
Source
Source
#1Brett D. M. Jones (CAMH: Centre for Addiction and Mental Health)H-Index: 2
#2Z. Jeff Daskalakis (CAMH: Centre for Addiction and Mental Health)H-Index: 70
Last. M. Ishrat Husain (CAMH: Centre for Addiction and Mental Health)H-Index: 1
view all 7 authors...
BACKGROUND Mood disorders, i.e. major depressive disorder (MDD) and bipolar disorders, are leading sources of disability worldwide. Currently available treatments do not yield remission in approximately a third of patients with a mood disorder. This is in part because these treatments do not target a specific core pathology underlying these heterogeneous disorders. In recent years, abnormal inflammatory processes have been identified as putative pathophysiological mechanisms and treatment target...
Source
#1Ben Carter ('KCL': King's College London)H-Index: 26
#2Rebecca Strawbridge ('KCL': King's College London)H-Index: 8
Last. Rachael Taylor ('KCL': King's College London)H-Index: 2
view all 15 authors...
Most interventions for treatment-resistant depression (TRD) are added as augmenters. We aimed to determine the relative effectiveness of augmentation treatments for TRD. This systematic review and network meta-analysis (NMA) sought all randomized trials of pharmacological and psychological augmentation interventions for adults meeting the most common clinical criteria for TRD. The NMA compared the intervention effectiveness of depressive symptoms for TRD augmentation. Of 36 included trials, 27 w...
Source
#1Muhammad I. Husain (U of T: University of Toronto)H-Index: 6
#2Bill Deakin (University of Manchester)H-Index: 16
Last. Allan H. Young ('KCL': King's College London)H-Index: 77
view all 5 authors...
Source
#1Filippo Corponi (UNIBO: University of Bologna)H-Index: 5
#2Gerard Anmella (University of Barcelona)H-Index: 2
Last. Sergey MosolovH-Index: 10
view all 14 authors...
Abstract Major Depressive Episode (MDE) is a transdiagnostic nosographic construct straddling Major Depressive (MDD) and Bipolar Disorder (BD). Prognostic and treatment implications warrant a differentiation between these two disorders. Network analysis is a novel approach that outlines symptoms interactions in psychopathological networks. We investigated the interplay among depressive and mixed symptoms in acutely depressed MDD/BD patients, using a data-driven approach. We analyzed 7 DSM-IV-TR ...
Source
#1Sameer Jauhar ('KCL': King's College London)H-Index: 17
#2Danilo Arnone ('KCL': King's College London)H-Index: 28
Last. Allan H. Young ('KCL': King's College London)H-Index: 77
view all 3 authors...
The review by Post and colleagues1 is important. The authors, with undoubted expertise in this field, describe measures addressing clinical issues in bipolar disorders (BD). They make a number of recommendations, covering the breadth of treatments, from illness stage (first episode mania, treatment resistance) to option(therapeutic approach, a broad range of pharmacotherapies, in addition to psychosocial interventions).
Source
#1Muhammad I. Husain (CAMH: Centre for Addiction and Mental Health)H-Index: 6
#2Imran B ChaudhryH-Index: 18
Last. Jeffrey H. Meyer (CAMH: Centre for Addiction and Mental Health)H-Index: 43
view all 14 authors...
Summary Background Several small studies suggest that the adjunctive use of anti-inflammatory agents might improve depressive symptoms in bipolar disorder. However, there are few well designed, appropriately powered clinical trials assessing the efficacy of these novel treatment strategies. We aimed to assess the efficacy of adjunctive minocycline or celecoxib in this setting. Methods This double-blind, 12-week, randomised, placebo-controlled trial was done in four outpatient psychiatric clinics...
2 CitationsSource
12345678910